Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of Thrombus Growth in Experimental Models of Thrombosis

Summary

The antithrombotic action of the highly effective synthetic thrombin inhibitor D-MePhe-Pro-Arg-H (GYKI-14766) was studied in various models of experimental thrombosis. The compound administered to rats and rabbits by i. v. bolus injections, continuous i. v. infusions, subcutaneously and orally, respectively, induced significant decrease in thrombus weight (i) in a quantitative venous thrombosis model with stasis based on vascular lesion in rats, (ii) in an extracorporeal arterio-venous shunt model in rabbits, and (iii) prevented the occlusion of the vessel in arterial thrombosis induced by mechanical damage in rats. By using the arterio-venous shunt model in rabbits the inhibitory effect on thrombus growth could be demonstrated as a function of dose and time in self-controlled experiments. Blood level of the inhibitor determined by a bioassay varied between 0.09-0.67 µg/ml whole blood when doses of 15 and 20 mg/kg were administered orally. A correlation was found between thrombin time, platelet aggregation induced by thrombin ex vivo and the weight of thrombi formed.

• References

• 1 Lóránd L, Nilsson JLG. Molecular approach for designing inhibitor to enzymes involved in blood clotting. In: Drug Design. Vol. 3 Academic Press; New York: 1972: 415-447
• 2 Tidwell RR, Webster WP, Shaver SR, Geratz JD. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb Res 1980; 19: 339-349
• 3 Geratz JD. Synthetic low molecular weight inhibitors of thrombin. Folia Haematol Leipzig 1972; 98: 455-470
• 4 Markwardt F, Klöcking HP, Nowak G. Antithrombin and Antiplasminwirkung von 4-Amidinophenylbrenztraubensäure (APPA) in vivo. Thromb Diath Haemorrh 1970; 24: 240-247
• 5 Blomback B, Blomback M, Olsson P, Svendsen L, Aberg C. Synthetic peptides with anticoagulant and vasodilating activity. Scand J Clin Lab Invest 1969; 24 (Suppl 107) 59
• 6 Okamoto S, Hijikata A, Kinjo K, Kikumotot R, Ohkubo K, Tonomura S, Tamao Y. A novel series of synthetic thrombin inhibitors having extremely potent and highly selective action. Kobe J Med Sci 1975; 21: 43-51
• 7 Bajusz S, Barabás é, Széll E, Bagdy D. Peptide aldehyde inhibitors of the fibrinogen-thrombin reaction. In: Peptides – Chemistry, Structure and Biology. Ann Arbor Sci Publ Inc; Ann Arbor, MI: 1975: 603-608
• 8 Markwardt F. Pharmacological control of blood coagulation by synthetic, low molecular weight inhibitors of clotting enzymes. A new concept of anticoagulants. Trends Pharm Sci 1980; 1: 152-157
• 9 Bagdy D, Barabás é, Bajusz S, Széll E. In vitro inhibition of blood coagulation by tripeptide aldehydes. A retrospective screening study focused on the stable D-MePhe-Pro-Arg-H sulfate. Thromb Haemostas 1992; 67 (3) 325-330
• 10 Bagdy D, Barabás é, Szabó AG, Bajusz S, Széll E. In vivo anti coagulant and antithrombotic effect of D-MePhe-Pro-Arg-H. Thromb Haemostas 1992; 61 (3) 357-365
• 11 Bajusz S, Széll E, Barabás é, Bagdy D. US Patent No. 4,399.065 (1983)
• 12 Bajusz S, Széll E, Barabás é, Bagdy D. US Patent No. 4,478.745 (1984)
• 13 Bajusz S, Széll E, Bagdy D, Diószegi M, Fittler ZS, Józsa F, Horváth GY, Tomori E. US Patent No. 4,703.036 (1987).
• 14 Bajusz S, Széll E, Bagdy D, Barabás é, Horváth Gy, Diószegi M, Fittler ZS, Szabó AG, Juhász A, Szilágyi G. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990; 33: 1729-1735
• 15 Pescador R, Porta R, Conz A, Mantovani M. A quantitative venous thrombosis model with stasis based on vascular lesion. Thromb Res 1989; 53: 197-201
• 16 Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1971; 26: 407-410
• 17 Smith JR, White AM. Fibrin, red cell and platelet interactions in an experimental model of thrombosis. Br J Pharmacol 1982; 77: 29-38
• 18 Kaiser B, Markwardt F. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. Thromb Haemostas 1986; 55 (2) 194-196
• 19 Philp RB. Experimental animal models of arterial thrombosis and the screening of platelet-inhibiting anti-thrombotic drugs. Meth Find Exptl Clin Pharmacol 1979; 1 (4) 197-224
• 20 Bills TK, Smith JB, Silver MJ. Selective release of arachidonic acid from the phospholipids of human platelets in response to thrombin. J Clin Invest 1977; 60: 1
• 21 Packham MA, Mustard F. Pharmacology of platelet affecting drugs. Circulation 1980; 62 (Suppl V) 26-40
• 22 IK-Kyung Jang, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81 (1) 219-225
• 23 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 24 Kettner Ch, Shaw E. D-Phe-Pro-Arg. Ch₂Cl – A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
• 25 Kovács A, Barabás é, Arányi P, Rabloczky Gy. Thrombin inhibitor (GYKI-14766) prevents thrombin induced vascular effects. Eur J Pharmacol 1990; 183: 1844-1845